As noted above, we have seen a wide range of flexibility by regulators to avoid delays in patient access to new and existing treatments. Regulators around the world have permitted electronic files for Certificates of Pharmaceutical Products and Good Manufacturing Practices, and accepted all regulatory filings electronically (e.g., meeting packages and annual reports). This reduction in administrative burden—without reduction in quality of information being provided—has simplified regulatory processes while maintaining compliance, and facilitated more efficient use of resources.